Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
Fierce Biotech6h
Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer
Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...